Pargolol

Pargolol

SCHEMBL1254705

C#CCOc1ccccc1OCC(O)CNC(C)(C)C

nearest known ligand 0.70

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.67
HTR1A P08908 2/20 0.64
ADRA2A P08913 2/20 0.64
ADRA2B P18089 1/20 0.64
MAOA P21397 1/20 0.64
HTR2B P41595 1/20 0.64
ADRB2 P07550 7/20 0.62
ADRB1 P08588 4/20 0.62
CYP2D6 P10635 3/20 0.59
CYP1A2 P05177 2/20 0.57
ADRA1A P35348 2/20 0.57
USP2 O75604 1/20 0.57
CHRM1 P11229 1/20 0.57
CYP2C9 P11712 1/20 0.57
DRD1 P21728 1/20 0.57
TBXA2R P21731 1/20 0.57
PTGS1 P23219 1/20 0.57
SLC6A2 P23975 1/20 0.57
SLC6A4 P31645 1/20 0.57
OPRM1 P35372 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pargolol SCHEMBL11757462 0.94 MAPT (0.60) MAPTHTR1AADRA2AADRA2BMAOA
SCHEMBL11870445 0.89 MAPT (0.78) MAPTHTR1AADRA2AADRA2BMAOA
Hydrochloric Acid SCHEMBL11870616 0.87 MAPT (0.81) MAPTHTR1AADRA2AADRA2BMAOA
SCHEMBL7320517 0.85 MAPT (0.59) MAPTHTR1AADRA2AADRA2BMAOA
SCHEMBL10668136 0.84 HTR1A (0.76) MAPTHTR1AADRA2AADRA2BMAOA
SCHEMBL11522246 0.82 CASR (0.63) ADRB2ADRB1CYP2D6SLC6A2SLC6A4
SCHEMBL10434592 0.82 ADRB2 (0.67) HTR1AADRA2AHTR2BADRB2ADRB1
SCHEMBL22640075 0.82 MAPT (0.68) MAPTHTR1AADRA2AADRA2BMAOA
SCHEMBL11201568 0.82 MAPT (0.68) MAPTHTR1AADRA2AADRA2BMAOA
SCHEMBL10774981 0.79 MAPT (0.68) MAPTHTR1AADRA2AADRA2BMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9585884-B2 Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2 AUSPEX PHARMACEUTICALS, INC. (US) 2017-03-07 US claimed
US-20170002015-A1 CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR AUSPEX PHARMACEUTICALS INC (US) 2017-01-05 US claimed
US-9498481-B2 Cyclopropyl modulators of P2Y12 receptor AUSPEX PHARMACEUTICALS, INC. (US) 2016-11-22 US claimed
US-20160193212-A1 CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR AUSPEX PHARMACEUTICALS INC (US) 2016-07-07 US claimed
US-9255104-B2 Cyclopropyl modulators of P2Y12 receptor AUSPEX PHARMACEUTICALS, INC. (US) 2016-02-09 US claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
US-20140286943-A1 CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR AUSPEX PHARMACEUTICALS INC (US) 2014-09-25 US claimed
US-20140107135-A1 PYRIMIDINONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 AUSPEX PHARMACEUTICALS, INC. (US) 2014-04-17 US claimed
US-8575348-B2 Quinolone inhibitors of lipoprotein-associated phospholipase A2 AUSPEX PHARMACEUTICALS, INC (US) 2013-11-05 US claimed
US-20120301458-A1 CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR AUSPEX PHARMACEUTICALS, INC. (US) 2012-11-29 US claimed
EP-0209897-A2 Peptide enzyme inhibitors MERCK & CO. INC. (US) 1987-01-28 EP claimed
EP-0163237-A2 Di- and tri-peptidal renin inhibitors MERCK & CO. INC. (US) 1985-12-04 EP claimed
EP-0157409-A2 Renin inhibitors containing 2-substituted statine MERCK & CO. INC. (US) 1985-10-09 EP claimed
EP-0156318-A2 C-terminal amide cyclic renin inhibitors containing peptide isosteres MERCK & CO. INC. (US) 1985-10-02 EP claimed
EP-0156322-A2 Renin inhibitors containing peptide isosteres MERCK & CO. INC. (US) 1985-10-02 EP claimed
EP-0129189-A2 Renin inhibitors containing a C-terminal amide cycle and compositions and combinations containing the same MERCK & CO. INC. (US) 1984-12-27 EP claimed
US-4303637-A Medication indicated for ocular hypertension ALZA CORPORATION (US) 1981-12-01 US claimed
EP-0037622-A2 Drug delivery insert for controlled ocular therapy ALZA CORPORATION (US) 1981-10-14 EP claimed
US-4281654-A Drug delivery system for controlled ocular therapy ALZA CORPORATION (US) 1981-08-04 US claimed
US-4039685-A 1-PHENOXY-2-HYDROXY-3-TERT.-BUTYLAMINO PROPANE ANTIARRHYTHMIC COMPOUNDS BOEHRINGER INGELHEIM GMBH (DT) 1977-08-02 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170002015-A1 CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR P2RY12, P2RY11, P2RY2 MAPT 4664/4885HTR1A 283/4885ADRA2A 111/4885
US-20160193212-A1 CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR P2RY12, P2RY11, P2RY2 MAPT 4664/4885HTR1A 283/4885ADRA2A 111/4885
US-20120301458-A1 CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR P2RY12, P2RY11, P2RY2 MAPT 4673/4885HTR1A 318/4885ADRA2A 91/4885
US-20140107135-A1 PYRIMIDINONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 PLA2G1B, PLA2G4A, PLA2G4B MAPT 4703/4885HTR1A 1445/4885ADRA2A 769/4885
US-20140286943-A1 CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR P2RY12, P2RY11, P2RY2 MAPT 4664/4885HTR1A 283/4885ADRA2A 111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.